Department of Neurology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China.
PLoS One. 2013 Aug 8;8(8):e68842. doi: 10.1371/journal.pone.0068842. eCollection 2013.
The association between aldosterone synthase (CYP11B2) C-344T gene polymorphism and ischemic stroke remains controversial and ambiguous. To better explain the association between CYP11B2 polymorphism and ischemic stroke risk, a meta-analysis was performed.
Based on comprehensive searches of Medline, Embase, Web of Science, CNKI and CBM databases, we identified and abstracted outcome data from all articles to evaluate the association between CYP11B2 polymorphism and ischemic stroke. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were performed in all genetic models. Fixed or random effects model was separately used depending on the heterogeneity between studies. Publication bias was tested by Begg's funnel plot and Egger's regression test.
A total of 12 studies including 3,620 ischemic stroke cases and 4,090 controls were identified. There was no statistical evidence of association between CYP11B2 C-344T polymorphism and ischemic stroke in all genetic models (allelic model: OR = 1.19, 95% CI = 0.95-1.49; additive model: OR = 1.43, 95% CI = 0.91-2.27; dominant model: OR = 1.30, 95% CI = 0.89-1.89; and recessive model: OR = 1.24, 95% CI = 0.96-1.60). On subgroup analysis by ethnicity, similarly results were found in both Asians and non-Asians. For Asians, the combined ORs and 95% CIs were (allelic model: OR = 1.07, 95% CI = 0.87-1.32; additive model: OR = 1.15, 95% CI = 0.77-1.71; dominant model: OR = 1.13, 95% CI = 0.92-1.38; and recessive model: OR = 1.09, 95% CI = 0.84-1.40). For none-Asians, the combined ORs and 95% CIs were (allelic model: OR = 1.58, 95% CI = 0.90-2.76; additive model: OR = 2.37, 95% CI = 0.79-7.05; dominant model: OR = 1.79, 95% CI = 0.77-4.19; and recessive model: OR = 1.80, 95% CI = 0.96-3.36).
The present meta-analysis suggested that CYP11B2 C-344T polymorphism was unlikely contribute to ischemic stroke susceptibility.
醛固酮合酶（CYP11B2）C-344T 基因多态性与缺血性卒中之间的关联仍存在争议和不明确。为了更好地解释 CYP11B2 多态性与缺血性卒中风险之间的关联，进行了荟萃分析。
基于 Medline、Embase、Web of Science、CNKI 和 CBM 数据库的全面检索，我们从所有文章中识别和提取结局数据，以评估 CYP11B2 多态性与缺血性卒中之间的关联。所有遗传模型均采用合并优势比（OR）及其 95%置信区间（CI）。根据研究间的异质性，分别采用固定效应模型或随机效应模型。采用 Begg 漏斗图和 Egger 回归检验来检测发表偏倚。
共纳入 12 项研究，包括 3620 例缺血性卒中病例和 4090 例对照。在所有遗传模型中，CYP11B2 C-344T 多态性与缺血性卒中均无统计学关联（等位基因模型：OR=1.19，95%CI=0.95-1.49；加性模型：OR=1.43，95%CI=0.91-2.27；显性模型：OR=1.30，95%CI=0.89-1.89；隐性模型：OR=1.24，95%CI=0.96-1.60）。按种族亚组分析，在亚洲人和非亚洲人中均得到了相似的结果。对于亚洲人，合并的 OR 值及其 95%CI 为（等位基因模型：OR=1.07，95%CI=0.87-1.32；加性模型：OR=1.15，95%CI=0.77-1.71；显性模型：OR=1.13，95%CI=0.92-1.38；隐性模型：OR=1.09，95%CI=0.84-1.40）。对于非亚洲人，合并的 OR 值及其 95%CI 为（等位基因模型：OR=1.58，95%CI=0.90-2.76；加性模型：OR=2.37，95%CI=0.79-7.05；显性模型：OR=1.79，95%CI=0.77-4.19；隐性模型：OR=1.80，95%CI=0.96-3.36）。
本荟萃分析提示 CYP11B2 C-344T 多态性与缺血性卒中易感性无关。
